ReviewGerms2022
Anti-virulence therapeutic strategies against bacterial infections: recent advances.
Review in Germs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed.
- Single- and Multiple-dose Pharmacokinetics, Excretion, Metabolism, and Safety of the Antivirulence Agent Fluorothiazinone in Healthy Adults.Pharmaceutical research · 2025Trial
- A secreted AIP-Like peptide fromVirulence · 2026Article
- A quorum sensing antagonist with dual bacterium- and host-directed anti-pathogenic activity againstVirulence · 2026Article
- Article
- Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas aeruginosa ExoU and improves corneal infection outcomes.PLoS pathogens · 2026Article
- New Proteins from Cold: Antibiofilm Activity of Cold-Azurin and PsyOmp38 Against Enterococcus faecalis and Klebsiella pneumoniae.Probiotics and antimicrobial proteins · 2026Article
- Emergence, evolution, and global dissemination of antimicrobial resistance: A One Health review.Archives of microbiology · 2026Review
- Gastrodin Inhibits Bacterial Biofilm Formation, Thereby Activating the Antibacterial Activity of Antibiotics.Molecules (Basel, Switzerland) · 2026Article
- Imidazo[2,1-Antibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial Armageddon: The Professional Guide to Conquering Antibiotic Resistance.Probiotics and antimicrobial proteins · 2026Article
- The ESKAPE Challenge: Understanding Resistance and Exploring Alternative Treatments.Antibiotics (Basel, Switzerland) · 2026Review
- Antivirulence Strategy againstACS omega · 2026Article
- Assessing of auto-inducer type-1 (AI-1) molecule N-(3-hydroxybutanoyl)-L-homoserine lactone responsible for quorum sensing mechanisms in marine pathogenic bacterium Vibrio harveyi.Archives of microbiology · 2026Article
- Understanding hemolysin: from bacterial toxin to emerging treatments.Archives of microbiology · 2026Review
- Antibacterial and Antibiofilm Efficacy of 2-Phenyl Ethyl Methyl Ether Against Multidrug-Resistant Klebsiella pneumoniae.Chemistry & biodiversity · 2026Article
- The Cyclic Adenosine Monophosphate Phosphodiesterase CpdA Modulates cAMP Homeostasis, Stress Adaptability, Biofilm Formation, Motility, Quorum Sensing and Antibiotic Resistance ofJournal of microbiology and biotechnology · 2026Article
- Targeted sortase A inhibition by novel peptidomimetic antivirulents against staphylococcal infections.Microbiology spectrum · 2026Article
- Mechanisms of Bacterial Resistance and Innovative Strategies to Overcome Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- In silico discovery of thioglycoside analogues as donor-site inhibitors of glycosyltransferase LgtC.Scientific reports · 2026Article
- Disease-Causing Mechanisms and Therapeutic Targets in Infectious Diseases: Implications for Clinical Management and Public Health.Biomedicines · 2026Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence and increasing prevalence of multidrug-resistant pathogens has become a major global healthcare problem. According to the World Health Organization if these trends continue, mortality from infection in 2050 will be higher than that from cancer. Microorganisms have various resistance mechanisms against different classes of antibiotics that emphasize the need for discovery of new antimicrobial compounds to treat bacterial infections. An interesting and new strategy for disarming pathogens is antivirulence therapy by blocking bacterial virulence factors or pathogenicity. Therefore, the use of these new pathoblockers could reduce the administration of broad-spectrum antimicrobials and prevalence of resistant strains. This review provides an overview of the antivirulence strategies published studies between years 2017 and 2021. Most antivirulence strategies focused on adhesins, toxins and bacterial communication. Additionally, targeting two-component systems and ncRNA elements were also examined in some studies. These new strategies have the potential to replace traditional antimicrobial agents and can be used to treat infections, especially infections caused by resistant pathogens, by targeting virulence factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.